Accueil
Envoyer à un ami
Imprimer
Grand
Petit
Partager
ACTUALITES

Boehringer Ingelheim launches RE-VECTO global program to capture data on Praxbind® ...


- 15 Août 2016 modifié le 1 Janvier 1970


  • Praxbind® (idarucizumab) is the specific reversal agent for the oral anticoagulant Pradaxa® (dabigatran)1,2
  • Praxbind® is already available in over 5,000 hospitals worldwide and is approved in over 35 countries3
  • RE-VECTO will provide insights into the diverse types of situations in which reversal of an anticoagulant is performed in clinical practice

(BUSINESS WIRE)-- Boehringer Ingelheim today announces its global RE-VECTO program for Praxbind® (idarucizumab), the specific reversal agent for Pradaxa® (dabigatran etexilate). ...

Source : http://me-newswire.net//news/18473/en...



ACTUALITES | INTERNATIONAL | TCHAD | POLITIQUE | CULTURE | EXCLUSIF | Revue de Presse | English News | 中國